Mary Hesdorffer, NP and Executive Director of the Mesothelioma Applied Research Foundation, discusses the latest advances in treatment options for mesothelioma. Results from early-stage clinical trials show a…
NEW YORK (Reuters Health) – Sorafenib delivered concurrently with transarterial chemoembolization (TACE) is safe in patients with intermediate hepatocellular cancer and does not lead to any unexpected adverse…
NEW YORK (Reuters Health) – As second-line treatment for locally advanced or metastatic non-small-cell lung cancer in Chinese patients, pemetrexed is as effective as docetaxel but with fewer…
NEW YORK (Reuters Health) – Parenteral hydration offers virtually no benefit to hospice patients with advanced cancer. There are no established standards for hydration at the end of…
NEW YORK (Reuters Health) – While oxybutynin is often used prophylactically to reduce irritative urinary symptoms related to intravesical bacillus Calmette-Guerin (BCG) therapy for bladder cancer, it actually…
NEW YORK (Reuters Health) – In patients with liver cancer related to hepatitis B virus (HBV) infection, giving nucleoside analogues after curative surgery appears to reduce the risk…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction chemotherapy, according to a French…
NEW YORK (Reuters Health) – Reduced-intensity conditioning that includes two daily 2.5-mg/kg doses of antithymocyte globulin before allogeneic stem-cell transplantation for hematologic malignancy significantly reduces graft-versus-host disease (GvHD)…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction…
One of the most common dietary supplements taken by many American adults is a daily multivitamin. Recently, a new study found that men over 50 who took a…